Patent leaders weigh in on gene patents at BIO
06 May 2010
Eileen McDermott, Chicago
The Myriad gene patent case was the highlight of the IP law sessions held at the 2010 BIO International Convention in Chicago this week
In a so-called super session featuring Eli Lilly senior vice president and general counsel Bob Armitage, USPTO director David Kappos and WIPO director-general Francis Gurry, Kappos said that the Office has spent considerable time thinking about the Myriad case.
He said that, unlike the district court, the USPTO continues to believe that a purified version of a naturally occurring organic compound should be eligible for patent protection.
“The USPTO has issued tens of thousands of patents covering isolated and purified DNA,” said Kappos. He added that the Office would continue to work with the biotechnology community on the issue “regardless of the outcome of the Federal Circuit appeal”. ...
Only subscribers have complete access to Managing IP Magazine,
log in or
subscribe now.
Alternatively take a
free trial, giving you 48-hour access to Managing IP Magazine (some articles and surveys may be excluded).
Subscribe Now
This article is available to subscribers. Please click subscribe to read the rest of the article.
Subscribe
Take a free trial
Please take a free 48-hour trial to gain limited access. Some articles and surveys may be excluded.
Take a free trial